Point72 Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-5,692,000
Closed -$3.93M 1307
2020
Q4
$3.93M Buy
5,692,000
+5,522,000
+3,248% +$11.8M 0.02% 619
2020
Q3
$383K Sell
170,000
-3,627,564
-96% -$10.4M ﹤0.01% 839
2020
Q2
$13.6M Sell
3,797,564
-2,302,436
-38% -$8.31M 0.09% 272
2020
Q1
$23.2M Buy
6,100,000
+5,600,000
+1,120% +$18.4M 0.19% 156
2019
Q4
$1.5M Buy
+500,000
New +$1.3M 0.01% 659

Other funds holding BMY.RT

Point72 Asset Management's BMY.RT Position: Q1 2021 in Review

Point72 Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 5,692,000 shares — an estimated $3.93M sold.

Point72 Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $23.2M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Point72 Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Point72 Asset Management sold 5,692,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.93M.
  • Point72 Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Point72 Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $23.2M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Point72 Asset Management's 13F filing for Q1 2021, filed 17 May 2021.